Venlafaxine and bupropion combination therapy in a case of treatment- resistant depression

Annals of Pharmacotherapy

Volumn 33, Issue 6, 1999, Pages 701-703

  Fatemi, S Hossein ^a   Emamian, Effat S ^b   Kist, David A ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Bupropion; Depression; Venlafaxine

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CLOMIPRAMINE; FLUOXETINE; LITHIUM; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; CASE REPORT; CHRONIC DISEASE; DEPRESSION; DRUG EFFICACY; FEMALE; GUILT; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; SOCIAL INTERACTION; SUICIDAL BEHAVIOR;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CHRONIC DISEASE; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE;

EID: 0033028872     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18249     Document Type: Article

References (18)

1. Kaplan HI, Sadock BJ, eds. Concise textbook of clinical psychiatry. Baltimore: Williams and Wilkins, 1996:156-64.
2. Kasper S, Fuger J, Moller H-J. Comparative efficacy of antidepressants. Drugs 1992;43(suppl 2):11-23.
3. Bodkin JA, Lasser RA, Wines JD, Gardner DM, Baldessarini RJ. Combining serotonin reuplake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-45.
4. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
5. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale: a procedure for measuring overall similarity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-71.
6. Product information. Effexor (venlafaxine hydrochloride). Philadelphia: Wyeth-Ayerst Laboratories, 1994.
7. Fogel P, Mamer OA, Chouinard G, Farrell PG. Determination of plasma bupropion and its relationship to therapeutic effect. Biomed Mass Spectrom 1984;11:629-32.
8. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992;32:714-24.
9. Ramcharitar V, Levine BS, Goldberger BA, Caplan YH. Bupropion and alcohol fatal intoxication. Forensic Sci Int 1992;56:151-6.
10. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35: 4493-7.
11. Guelfi JD, White C, Hackett D, Guichoux JY, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-8.
12. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-43.
13. Derivan A, Entsuah AR, Kikta D. Venlafaxine: measuring the onset of antidepressant action. Psychopharmacol Bull 1995;31:43947.
14. Kent JM, Gorman JM. Venlafaxine. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press textbook of psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press, Inc., 1998;301-6.
15. Mehta NB. The chemistry of bupropion. J Clin Psychiatry 1983;44(suppl 5 sec 2):56-9.
16. Golden RN. Diethylpropion, bupropion, and psychoses (letter). Br J Psychiatry 1988;153:265-6.
17. Davidson JRT, Connor KM. Bupropion sustained release. A therapeutic overview. J Clin Psychiatry 1998;59(suppl 4):25-31.
18. Kirsch MA, Louie AK. Combination treatment with venlafaxine and bupropion (letter). Am J Psychiatry 1999;156:494.